Eortc
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Private
- Established
- 1962-01-01
- Employees
- 251
- Market Cap
- -
- Website
- https://www.eortc.org
Clinical Trials
79
Active:73
Completed:3
Trial Phases
3 Phases
Phase 1:53
Phase 2:3
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
Phase 1
53 (91.4%)Phase 2
3 (5.2%)Phase 3
2 (3.4%)No trials found
News
Phase 3 Trial Shows Promise for Adjuvant BRAF/MEK Inhibitor Combination in High-Risk Melanoma
The phase 3 EORTC-2139-MG/Columbus-AD trial demonstrated that adjuvant encorafenib plus binimetinib improved 12-month recurrence-free survival to 86% versus 70% with placebo in patients with stage IIB/C BRAF V600-mutant melanoma.
EORTC and Medidata Extend Partnership to Enhance Oncology Clinical Trials
The European Organisation for Research and Treatment of Cancer (EORTC) has extended its partnership with Medidata for four years.